-
公开(公告)号：WO2011153514A9
公开(公告)日：2012-04-05
申请号：PCT/US2011039190
申请日：2011-06-03
Applicant: PHARMACYCLICS INC , BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/519 , A61K31/505 , A61P35/00 , A61P35/02
CPC classification number: A61K31/519 , A61K9/0014 , A61K9/0031 , A61K9/0048 , A61K9/0056 , A61K9/007 , A61K9/06 , A61K31/195 , A61K31/337 , A61K31/4184 , A61K31/436 , A61K31/437 , A61K31/454 , A61K31/4745 , A61K31/475 , A61K31/573 , A61K31/606 , A61K31/664 , A61K31/675 , A61K31/69 , A61K31/7032 , A61K31/704 , A61K31/7076 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K45/06 , C07D487/04 , A61K2300/00
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
-
公开(公告)号：EP2771010A4
公开(公告)日：2015-04-01
申请号：EP12841068
申请日：2012-10-19
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/52 , A61K31/337 , A61K31/4184 , A61K31/454 , A61K31/475 , A61K31/4965 , A61K31/519 , A61K31/5383 , A61K31/704 , A61K31/7076 , A61P35/00
CPC classification number: A61K31/519 , A61K31/337 , A61K31/4184 , A61K31/454 , A61K31/475 , A61K31/4965 , A61K31/52 , A61K31/5383 , A61K31/704 , A61K31/7076 , A61K45/06 , C12Q1/6886 , G01N33/57484 , A61K2300/00
-
公开(公告)号：EP2575818A4
公开(公告)日：2013-11-06
申请号：EP11790524
申请日：2011-06-03
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/195 , A61K31/436 , A61K31/454 , A61K31/475 , A61K31/519 , A61K31/573 , A61K31/606 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7076 , A61P35/00 , A61P35/02
CPC classification number: A61K31/519 , A61K9/0014 , A61K9/0031 , A61K9/0048 , A61K9/0056 , A61K9/007 , A61K9/06 , A61K31/195 , A61K31/337 , A61K31/4184 , A61K31/436 , A61K31/437 , A61K31/454 , A61K31/4745 , A61K31/475 , A61K31/573 , A61K31/606 , A61K31/664 , A61K31/675 , A61K31/69 , A61K31/7032 , A61K31/704 , A61K31/7076 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K45/06 , C07D487/04 , A61K2300/00
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
-
公开(公告)号：MX2012014049A
公开(公告)日：2013-03-12
申请号：MX2012014049
申请日：2011-06-03
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , LOURY DAVID J , MODY TARAK D , FYFE GWEN , HEDRICK ERIC
IPC: A61K31/519 , A61K31/505 , A61P35/00 , A61P35/02
Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.
-
公开(公告)号：SG186077A1
公开(公告)日：2013-01-30
申请号：SG2012087243
申请日：2011-06-03
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
-
Patent Agency Ranking
公开(公告)号：PH12021550758A1
公开(公告)日：2022-02-21
申请号：PH12021550758
申请日：2021-04-06
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/505 , A61K31/519 , A61P35/00 , A61P35/02
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
-
公开(公告)号：CA2851808A1
公开(公告)日：2013-04-25
申请号：CA2851808
申请日：2012-10-19
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/52 , A61K31/519 , A61P35/00
Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.
-
公开(公告)号：CL2012003381A1
公开(公告)日：2013-03-22
申请号：CL2012003381
申请日：2012-11-30
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
Abstract: Compuestos derivados de 4-amino-3-fenil-1h-pirazolo[3,4-d]pirimidina; y compuesto (r)-1-(3-(4-amino-3-(4-fenoxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona para tratar el linfoma de Hodgkin retraído o refractario y la leucemia linfocítica crónica retraída o refractaria o linfoma linfocítico pequeño.
-
公开(公告)号：CA2800913A1
公开(公告)日：2011-12-08
申请号：CA2800913
申请日：2011-06-03
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/519 , A61K31/505 , A61P35/00 , A61P35/02
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
-
公开(公告)号：CA2851808C
公开(公告)日：2021-04-13
申请号：CA2851808
申请日：2012-10-19
Applicant: PHARMACYCLICS INC
Inventor： BUGGY JOSEPH J , ELIAS LAURENCE , FYFE GWEN , HEDRICK ERIC , LOURY DAVID J , MODY TARAK D
IPC: A61K31/519 , A61K31/343 , A61K39/395 , A61P35/00 , A61P35/02
Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.023 seconds)
